This paper is only available as a PDF. To read, Please Download here.
Abstract
This pilot study was done to assess the efficacy and toxicity of intravenous ceftazidime
and ciprofloxacin in patients developing febrile neutropenia while undergoing high-dose
myeloablative therapy and hematopoietic stem cell transplantation (HSCT). All patients
undergoing high-dose chemoradiotherapy and HSCT for leukemias, lymphomas, multiple
myeloma, and solid tumors received open-label ceftazidime 2 g intravenously every
8 hours and ciprofloxacin 400 mg intravenously every 12 hours if they developed fever
while they were neutropenic. Success with or without modification of this regimen
was defined as survival through the neutropenic period; failure was defined as death
secondary to infection. Among 45 patients treated with this regimen, the success rate
was 98%. Sixty-two percent (28 of 45) of the patients achieved defervescence within
48 to 72 hours and remained afebrile without regimen modification. In 16 patients
(36%) the regimen was modified because of persistent fever. The combination of ceftazidime
and ciprofloxacin as initial empiric antibacterial therapy in febrile neutropenic
patients undergoing myeloablative therapy and HSCT appears to be highly effective
and is associated with minimal toxicity.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia.Ann Intern Med. 1966; 64: 328-340
- Infectious complications in the pediatric cancer patient.in: Pizzo PA Poplack DG Principles and Practice of Pediatric Oncology. Lippincott, Philadelphia1989: 837-867
- A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever.Am J Med. 1989; 87 (Suppl 5A): 269-273
- Empiric treatment of infections in neutropenic patients with cancer.Rev Infect Dis. 1983; 5: 21-31
- Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: An overview.Eur J Cancer Clin Oncol. 1989; 25: 37-42
- Empiric therapy with carbenicillin and gentamycin for febrile patients with cancer and granulocytopenia.NEJM. 1971; 28: 1061-1066
- Monotherapy for fever and neutropenia in cancer patients. A randomized comparison of ceftazidime versus imipenem.Clin Oncol. 1995; 13: 165-176
- Imipenem-cilastatin monotherapy in juvenile cancer patients with neutropenia.Pediatr Hematol Oncol. 1990; 7: 229-241
- Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: An open study in patients with hematologic malignancies.Eur J Haematol. 1991; 46: 42-46
- Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.Antimicrob Agents Chemother. 1990; 27: 745-748
- A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.NEJM. 1986; 315: 552-558
- A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.Arch Intern Med. 1992; 152: 283-291
- Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: A meta-analysis.J Infect Dis. 1992; 164: 907-916
- Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.Am J Med. 1985; 78 (Suppl 5A): 62-72
- Treatment of severe pneumonia in hospitalized patients: Results of a multi-center, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin Niederman MS.Antimicrob Agents Chemother. 1994; 38: 547-557
- Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.Antimicrob Agents Chemother. 1989; 33: 87-91
- A randomized study of teicoplanin plus ciprofloxacin versus gentamycin plus piperacillin for the empirical treatment of fever in neutropenic patients.Br J Haematol. 1990; 76: 10-13
- Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial.Am J Med. 1995; 98: 224-231
- Self-administered antibiotic therapy for chemotherapy-induced low-risk febrile neutropenia in patients with non-hematologic neoplasms.Clin Infect Dis. 1994; 19: 522-527
- Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram negative bacteremia in cancer patients with granulocytopenia.NEJM. 1987; 317: 1697-1698
Article info
Identification
Copyright
© 1997 Published by Elsevier Inc.
